| Hopehealth Massachusetts, Inc 765 Attucks Lane, Hyannis, MA, 02601 | |
| (508) 957-0200 |
News Archive
Summer is in full swing and injuries from gasoline and other accelerants are on the rise. The University of Michigan Health System's Trauma Burn Center saw 14 such burns in the past month.
With the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across most of the world, scientists are working strenuously to find effective therapies or vaccines. Most strategies being worked on at present are targeting viral entry into the host cells, mainly through the interaction of the SARS-CoV-2 S protein with the angiotensin-converting enzyme 2 (ACE2) receptor.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.
Chelsea Therapeutics International, Ltd. reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period.
A biotechnology startup enabled by UC Davis, Molecular Matrix Inc., has received Food and Drug Administration clearance for a carbohydrate-based polymer that can help injured bones heal and regrow.
› Verified 1 days ago
| Name | Hopehealth Massachusetts, Inc |
|---|---|
| Location | 765 Attucks Lane, Hyannis, Massachusetts |
| Hospice ID | 221512 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| SSA county code | 000 |
News Archive
Summer is in full swing and injuries from gasoline and other accelerants are on the rise. The University of Michigan Health System's Trauma Burn Center saw 14 such burns in the past month.
With the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across most of the world, scientists are working strenuously to find effective therapies or vaccines. Most strategies being worked on at present are targeting viral entry into the host cells, mainly through the interaction of the SARS-CoV-2 S protein with the angiotensin-converting enzyme 2 (ACE2) receptor.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.
Chelsea Therapeutics International, Ltd. reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period.
A biotechnology startup enabled by UC Davis, Molecular Matrix Inc., has received Food and Drug Administration clearance for a carbohydrate-based polymer that can help injured bones heal and regrow.
› Verified 1 days ago
| NPI Number | 1861425688 |
| Organization Name | Hopehealth Massachusetts, Inc. |
| Address | 765 Attucks Lane Hyannis, Massachusetts, 02601 |
| Phone Number | (508)957-0200 |
News Archive
Summer is in full swing and injuries from gasoline and other accelerants are on the rise. The University of Michigan Health System's Trauma Burn Center saw 14 such burns in the past month.
With the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across most of the world, scientists are working strenuously to find effective therapies or vaccines. Most strategies being worked on at present are targeting viral entry into the host cells, mainly through the interaction of the SARS-CoV-2 S protein with the angiotensin-converting enzyme 2 (ACE2) receptor.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.
Chelsea Therapeutics International, Ltd. reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period.
A biotechnology startup enabled by UC Davis, Molecular Matrix Inc., has received Food and Drug Administration clearance for a carbohydrate-based polymer that can help injured bones heal and regrow.
› Verified 1 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 99.9 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.6 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 99.9 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 100.0 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
| Patients who got timely treatment for shortness of breath | 99.2 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 99.7 | 93.3 |
News Archive
Summer is in full swing and injuries from gasoline and other accelerants are on the rise. The University of Michigan Health System's Trauma Burn Center saw 14 such burns in the past month.
With the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across most of the world, scientists are working strenuously to find effective therapies or vaccines. Most strategies being worked on at present are targeting viral entry into the host cells, mainly through the interaction of the SARS-CoV-2 S protein with the angiotensin-converting enzyme 2 (ACE2) receptor.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.
Chelsea Therapeutics International, Ltd. reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period.
A biotechnology startup enabled by UC Davis, Molecular Matrix Inc., has received Food and Drug Administration clearance for a carbohydrate-based polymer that can help injured bones heal and regrow.
› Verified 1 days ago
| Home Health Aides | 37.95 |
| Counselors | 3.6 |
| Licensed Practical or Vocational Nurses | 3.15 |
| Medical Social Workers | 8.85 |
| Physicians | 1.8 |
| Registered Nurses | 70.75 |
| Total Employees | 126.1 |
|---|
News Archive
Summer is in full swing and injuries from gasoline and other accelerants are on the rise. The University of Michigan Health System's Trauma Burn Center saw 14 such burns in the past month.
With the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across most of the world, scientists are working strenuously to find effective therapies or vaccines. Most strategies being worked on at present are targeting viral entry into the host cells, mainly through the interaction of the SARS-CoV-2 S protein with the angiotensin-converting enzyme 2 (ACE2) receptor.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.
Chelsea Therapeutics International, Ltd. reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period.
A biotechnology startup enabled by UC Davis, Molecular Matrix Inc., has received Food and Drug Administration clearance for a carbohydrate-based polymer that can help injured bones heal and regrow.
› Verified 1 days ago
| Hopehealth Massachusetts, Inc Location: 765 Attucks Lane, Hyannis, Massachusetts, 02601 Phone: (508) 957-0200 |